Blood
Articles in this Issue
Patient satisfaction with outpatient management of sickle cell pain crisis
Abstract Introduction: Vaso-occlusive crisis (VOC) causing pain is the most common reason for patients with sickle cell disease (SCD) to pre...
Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma
Abstract Background: Hodgkin lymphoma (HL) is a rare B-cell lymphoma with approximately 8,570 new cases diagnosed annual...
Altered osteoblast populations dynamics underlie myeloma progression from precursors diseases in bone microenvironment
Abstract Uncoupled bone-remodelling process characterizes the development of multiple myeloma (MM)-related bone disease, where impaired oste...
Long-term event-free survival in patients with IGHV-mutated high-count monoclonal B-cell lymphocytosis and atypical, non-CLL-like phenotypes
Abstract Monoclonal B-cell lymphocytosis (MBL) is a frequent precursor of chronic lymphocytic leukemia (CLL) and among the most common prema...
Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data
Abstract Introduction Waldenström's macroglobulinemia (WM) is a rare, indolent, IgM-producing lymphoplasmacytic lymphoma with diverse clinic...
Redefining hematology referral thresholds for eosinophilia: A 10-year experience at an academic medical center
Abstract Background: Eosinophilia, typically defined as an absolute eosinophil count (AEC) exceeding 0.5 x 10 9/L, is a common laboratory fi...
Management of breakthrough bleeds in participants with hemophilia Α or Β without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study
Abstract Background Marstacimab is a monoclonal antibody that targets the tissue factor pathway inhibitor to rebalance hemostasis. It is app...
Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontlinetherapy for mantle cell lymphoma: Final results of polaris multicenter phase II study
Abstract Introduction: Despite the established efficacy of chemoimmunotherapy in untreated mantle cell lymphoma (MCL), its clinical utility...
Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy
Abstract Background: Cytopenias are common following chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed refracto...
Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study
Abstract Introduction Odronextamab (Odro), a CD20×CD3 bispecific antibody, showed promising efficacy as first-line monot...
Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.
Abstract Introduction: Targeting BCMA has shown promising activity in multiple myeloma (MM). However, durability of responses has been somew...
Bifidobacterium BX520 supplementation prevents neuroinflammation in necrotizing enterocolitis by inhibiting IDO1 through the gut-brain axis
Abstract Background Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease in premature infants. Among children who have survi...
Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group
Abstract Introduction: MECOM-rearranged (r) acute myeloid leukemia (AML) is a distinct WHO-defined genetic subtype and includes cases with i...
Less plasma, less drama: A quality improvement initiative to reduce inappropriate plasmatransfusions across community hospitals in the niagara region.
Abstract Background Plasma transfusion has limited clinical indications, primarily for patients with coagulopathy and active...
IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment
Abstract Introduction: Cereblon E3 ligase modulating drugs (CELMoDs) represent a novel class of immunomodulatory agents that target IKZF1 an...
Omic evaluation of G-CSF-induced changes in bone marrow: A focus on lipid metabolism
Abstract Introduction: Granulocyte Colony Stimulating Factor (G-CSF) is a mobilizing factor of hematopoietic stem cells (HSC). Protein and l...
Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens
Abstract Background Elranatamab (ELRA) is a B-cell maturation antigen (BCMA)xCD3 bispecific antibody approved for the treatment of relapsed/...
Tambiciclib (SLS009), a novel, potent CDK9 inhibitor is effective in killing ASXL1 mutated and TP53 knockout Acute Myeloid Leukemia cell lines
Abstract CDK9 plays an integral role throughout the cell cycle as a regulator of transcription elongation through RNA polymerase II. CDK9 is...
Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition
Abstract Background CD19-directed CAR T-cell therapy (CART) is the standard of care for relapsed/refractory large B-cell lymphoma (R/R LBCL)...
Management of acute coronary syndrome and surgical revascularization in a patient with severe Hemophilia A on emicizumab
Abstract Patients with Hemophilia A (HA) have been observed to have lower rates of cardiovascular mortality compared to the general populati...
Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population
Abstract Introduction The 2022 European Leukemia Network (ELN) risk stratification system for acute myeloid leukemia (Dohner et al, Blood, 2...
Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial
Abstract Introduction Venous thromboembolism (VTE) affects 1 in 200 hospitalized children. In adults, lower socioeconomic status, Black race...
Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3
Abstract Pure erythroid leukemias (PEL) and sarcomas driven by NFIA::CBFA2T3 are rare and aggressive malignancies. They most often present i...
Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia
Abstract Background and Significance: The combination of venetoclax and a hypomethylating agent (Ven/HMA) is the standard frontline (1L) the...
Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for myelofibrosis (MF), but it...